Sunset haematology: Improving the end-of-life journey for patients and caregivers, in patients with haematologic malignancies

Philip Rowlings, Alison Chandler, Nina Vogel, Phillip Collard, Allison Boyes et Robert Gale

Volume 11, numéro 1S, supplément, 2024
Congress 2023

URI : https://id.erudit.org/iderudit/1110260ar

Citer ce document
POSTER

SUNSET HAEMATOLOGY: IMPROVING THE END-OF-LIFE JOURNEY FOR PATIENTS AND CAREGIVERS, IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES

Philip Rowlings¹,²,³,⁴,⁵, Alison Chandler¹,², Nina Vogel¹,³,⁴, Phillip Collard¹, Allison Boyes³,⁵, Robert Gale⁶

¹* Corresponding author: Department of Haematology, Calvary Mater Newcastle Hospital, Waratah, Newcastle, New South Wales, Australia
phil_rowlings@icloud.com
2 New South Wales Health Pathology, Hunter, Rankin Park, New South Wales, Australia
3 University of Newcastle, Callaghan, New South Wales, Australia
4 Hunter New England Local Health District, New South Wales, Australia
5 Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
6 Imperial College of Science, Technology and Medicine, South Kensington, London, UK

Keywords: Haematologic Malignancies, End-of-life care

BACKGROUND AND AIM

Haematologic Malignancies (HM) are diverse diseases with differing illness trajectories and therapeutic pathways. Unfortunately, HM patients may rapidly and unexpectedly clinically deteriorate, resulting in suboptimal engagement of palliative and end-of-life (EOL) care. Compared to patients with solid tumors, HM patients have many different factors affecting their end-of-life (EOL) journey. Uniquely, a subset of HM patients with bone marrow failure (BMF) can be supported for significant, but highly
variable, periods of time with red blood cell transfusions (RBCT), platelet transfusions (PT) and prophylactic antibiotics. Availability of chronic RBCTs and PTs make HM patients with BMF similar to elderly and poor prognosis patients with end stage kidney disease (ESKD). Multidisciplinary Palliative Supportive Care programs have been shown to be effective for these EKSD patients and may serve as supportive care models for EOL journey in HM patients. This project is a pilot study aiming to provide a template for management of EOL for patients with HM with BMF, and their care-givers.

METHODS

Three components are being developed: 1) Survey of patient opinions around treatment decision-making. 2) Analyses of the impact of patient, disease, and treatment factors on the probability of survival from start of PT, to inform patients. 3) Collaborative involvement between Haematology and Palliative Care staff involved in the local ESKD program, to develop a template for earlier EOL pathway planning in HM patients.

CONCLUSION

Progress of work to date will be presented, including preliminary findings and next steps.